IntelGenx (OTCQX:IGXT; TSXV:IGX) announced that its plant, following a Good Manufacturing Practices (GMP) inspection performed by Health Canada, has obtained an amended Drug Establishment License (DEL) for manufacturing activities.Read More
The U.S. Patent and Trademark Office granted a notice of allowance to IntelGenx (OTCQX:IGXT; TSXV:IGX) for a patent entitled, "Device and Method of Treating Conditions Associated with Neuroinflammation."Read More
IntelGenx (TSXV:IGX; OTCQX:IGXT) announced that a decision by the U.S. District Court for the District of Delaware determined that the process used to manufacture IntelGenx's and Par Pharmaceutical's buprenorphine/naloxone sublingual film product for the treatment of opiate addiction does not infringe MonoSol Rx U.S. Patent No. 8,900,497.Read More
IntelGenx (OTCQX:IGXT; TSXV:IGX;) has received a notice of allowance from the U.S. Patent and Trademark Office for a patent application entitled, “Solid oral film dosage forms and methods for making same.”Read More
IntelGenx Technologies (OTCQX:IGXT; TSXV:IGX) has received a U.S. from the United States Patent and Trademark Office entitled, "Film dosage form with extended release mucoadhesive particles."Read More
IntelGenx (TSX-V:IGX; OTCQX:IGXT) and Tetra Bio-Pharma (CSE:TBP; OTC: GRPOF) announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol.Read More
IntelGenx (OTCQX:IGXT; TSX-V:IGX) entered into a co-development and commercialization agreement with Endo Ventures for a new product utilizing IntelGenx' proprietary VersaFilm for the USA market.Read More
IntelGenx (OTCQX:IGXT; TSX-V:IGX) and RedHill Biopharma (NASDAQ,:RDHL; TASE:RDHL) have signed an exclusive license agreement with Pharmatronic for the commercialization of Rizaport in South Korea.Read More
IntelGenx (OTCQX:IGXT; TSX-V:IGX) strengthened its relationship with Chemo Group by signing a term sheet for co-development and commercialization of a generic tablet for the central nervous system (CNS) on a worldwide basis.Read More
IntelGenx (OTCQX:IGXT; TSX-V:IGX) has signed a binding term sheet to license Eli Lilly's tadalafil dosing patent. Any exclusivity associated with the tadalafil compound patent is not affected by the agreement.Read More
IntelGenx (OTCQX:IGXT; TSX-V:IGX) has entered into a licensing, development and supply agreement with closely-held Chemo Group, granting Chemo the exclusive license to commercialize two generic products for the U.S. market and one product on a worldwide basis.
The Chemo Group is a global pharmaceutical company with over 5,000 employees, operations in over 40 countries and annual revenue of more than $1.2-billion.Read More
IntelGenx (OTCQX:IGXT; TSX-V:IGX) has completed a pilot clinical study for montelukast VersaFilm that demonstrated a significantly improved pharmacokinetic profile against the reference product.
Montelukast is a unique drug repurposing opportunity for the treatment of degenerative diseases of the brain, such as mild cognitive impairment and Alzheimer’s disease.Read More
IntelGenx (OTCQX:IGXT; TSX-V:IGX) has sold its royalty on future sales of Forfivo XL to SWK Holdings for $6-million.
Forfivo XL (bupropion extended release) is the first 450-milligram bupropion hydrogen chloride tablet indicated for major depressive disorder approved by the FDA. Patent protection for Forfivo XL in the U.S. expires in 2027, with an authorized generic entering the market in January 2018.Read More